Genetic variants linked to T2DM risk in Kurdish populations
Authors Golsheh S, Keshavarzi F
Received 29 September 2018
Accepted for publication 5 March 2019
Published 5 April 2019 Volume 2019:12 Pages 431—437
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Dr Konstantinos Tziomalos
This paper has been retracted
Shadi Golsheh,1 Fatemeh Keshavarzi2
1Department of Biology, Kurdistan Science and Research Branch, Islamic Azad University, Sanandaj, Iran; 2Department of Biology, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran
Background: The polymorphisms of the C–C chemokine receptor type 5 (CCR5) and the insulin receptor substrate 1 (IRS1) have been studied as candidates for the susceptibility to develop type 2 diabetes mellitus (T2DM). CCR5 is a chemokine receptor, and the polymorphisms in the promoter region of this receptor are being studied as candidates for the susceptibility to develop T2DM. Also, IRS1 is a critical factor in the signaling pathway for insulin, and mutations in this gene have been reported, which contribute to the ability to develop T2DM. The aim of the current study was to determine the relationship between CCR5 (59029A/G) and IRS1 (rs10498210) polymorphisms with T2DM in Sanandajian patients.
Methods: Genomic DNA was isolated from 200 healthy individuals and 220 Kurdish T2DM patients by salt extraction method and the polymorphisms were examined by restriction fragment length polymorphism (RFLP) method and then the results were analyzed using Chi-square test.
Results: The frequency of AA genotype in 220 Kurdish patients for both genes CCR5 (OR=1.9, P=0.02) and IRS1 (OR [95% CI]=2.62, P=0.02) were significantly more than controls. There was no significant association between AG or GG genotypes in with T2DM.
Conclusion: The presence of AA homozygote alleles in both loci of IRS1 (rs10498210) and CCR5 (59029A/G) genes increased the risk of T2DM.
Keywords: IRS1 (rs10498210), CCR5 (59029A/G), type 2 diabetes, Kurdish patients
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]